At present, the prevalence of adult diabetes is 8-10%, and the number of diabetic patients in the world is conservatively estimated to be 350 million. Diabetic nephropathy and diabetic retinopathy are the two major microvascular complications of diabetic patients, and their lethality and harm, on the whole, exceed the other two complications, diabetic foot disease and other complications. Among them, the prevalence of diabetic nephropathy is as high as 20-50% in the diabetic population, especially in patients with diabetes for more than 10 years, the prevalence rate can be as high as 70%, and half of them will develop chronic renal damage and renal failure. Diabetic nephropathy is the first cause of renal maintenance dialysis in end-stage renal disease in Europe and the United States. Diabetic retinopathy is also the leading cause of insomnia in diabetic patients. Immune factors have been clearly confirmed to play an important pathogenic role in type 1 diabetes, but the role of immune factors in the pathogenesis of type 2 diabetes remains to be further explored. In addition, we are not clear about the role of immune-involved inflammatory response plays in diabetic microvascular disease, and do not know whether it can be a potential intervention target. Answering these questions will provide important targets to overcome diabetes and effectively prevent the progress of diabetic microvascular complications.
The goal of the Research Topic is to explore the immune (inflammation) regulation and mediating mechanisms during the pathogenesis of diabetes and diabetic microvascular complications (diabetic nephropathy, diabetic retinopathy), and to find potential disease intervention targets in related treatments. We welcome manuscripts that include, but are not limited to, the following aspects:
? Immune-Mediated Mechanisms of the Development of Diabetes
? The role of immune-mediated pancreatic ß-cell function decline in the development of type 2 diabetes mellitus
? Potential immunotherapy prospects for diabetes
? Involvement and mechanism of immune inflammation in the pathogenesis of diabetic nephropathy
? Immune pathogenic mechanisms in the development of diabetic retinopathy
At present, the prevalence of adult diabetes is 8-10%, and the number of diabetic patients in the world is conservatively estimated to be 350 million. Diabetic nephropathy and diabetic retinopathy are the two major microvascular complications of diabetic patients, and their lethality and harm, on the whole, exceed the other two complications, diabetic foot disease and other complications. Among them, the prevalence of diabetic nephropathy is as high as 20-50% in the diabetic population, especially in patients with diabetes for more than 10 years, the prevalence rate can be as high as 70%, and half of them will develop chronic renal damage and renal failure. Diabetic nephropathy is the first cause of renal maintenance dialysis in end-stage renal disease in Europe and the United States. Diabetic retinopathy is also the leading cause of insomnia in diabetic patients. Immune factors have been clearly confirmed to play an important pathogenic role in type 1 diabetes, but the role of immune factors in the pathogenesis of type 2 diabetes remains to be further explored. In addition, we are not clear about the role of immune-involved inflammatory response plays in diabetic microvascular disease, and do not know whether it can be a potential intervention target. Answering these questions will provide important targets to overcome diabetes and effectively prevent the progress of diabetic microvascular complications.
The goal of the Research Topic is to explore the immune (inflammation) regulation and mediating mechanisms during the pathogenesis of diabetes and diabetic microvascular complications (diabetic nephropathy, diabetic retinopathy), and to find potential disease intervention targets in related treatments. We welcome manuscripts that include, but are not limited to, the following aspects:
? Immune-Mediated Mechanisms of the Development of Diabetes
? The role of immune-mediated pancreatic ß-cell function decline in the development of type 2 diabetes mellitus
? Potential immunotherapy prospects for diabetes
? Involvement and mechanism of immune inflammation in the pathogenesis of diabetic nephropathy
? Immune pathogenic mechanisms in the development of diabetic retinopathy